CRPOF - Ceapro completes enrollment in beta glucan cholesterol study

Ceapro (CRPOF) announces the completion of patient enrollment in its comparison study evaluating high-medium molecular weight beta glucan as a stand-alone or add-on therapy to statins in subjects with hyperlipidemia, a condition in which high levels of fat build up in the blood.The company expects to report topline data from the study in the fourth quarter of 2021.The multicenter, randomized, double-blind, parallel group, placebo-controlled study is being conducted to determine the efficacy and safety of high-medium molecular weight beta glucan in subjects with the condition (LDL-C level >130 mg/d L (3.37 mmol/L).The 18 to 24-month study enrolled about 264 subjects who cannot tolerate high doses of current treatments.Enrolled patients were randomized to receive either placebo, low, medium or high doses of beta glucan (500 mg tablet) as add-on therapy, or not, to atorvastatin 10 mg - 20 mg or an equivalent statin for a 12-week treatment period. The primary efficacy endpoint

For further details see:

Ceapro completes enrollment in beta glucan cholesterol study